A meta-analysis was performed to compare the risk of pared to other active controls or placebo (odds ratios [OR] 0.9; 95% CI 0.7---1.46 and 0.5; 95% CI 0.2---1.3). These serious adverse events associated with the use of all formulations of isradipine, when used as monotherapy major adverse events included angina, fatal and nonfatal myocardial infarction, stroke and overall mortality. in hypertension, to active drug or placebo controls. Eligible studies totalled 65 published and unpublished ranIsradipine sustained release could be compared only to placebo, based on available data, and shows a lower domised controlled trials involving 9903 subjects and 10 675 treatment exposures: 4492 to isradipine, 1473 to risk of withdrawals (OR 0.5; 95% CI 0.3---0.9), and a similar trend was observed for major adverse events, (OR isradipine sustained release, 2768 to other active drugs, and 1942 to placebo. Mortality, cardiovascular out-0.8; 95% CI 0.3-2.5). Published and unpublished randomised controlled trials were analysed in separate comes, other serious incident illnesses, such as cancer, and withdrawals were sought. Seventy-five per cent of meta-analyses and later combined when this sensitivity analysis of risk showed no differences between the the isradipine exposures were to standard-release formulations and 25% were to sustained-release formugroups. In conclusion, we find no evidence for increased risk of serious adverse events in patients lations. Overall, isradipine therapy shows no difference in risk of major adverse events or withdrawals comreceiving isradipine as monotherapy for hypertension.
Introduction
CCBs was also published. 11 This study reported an Calcium channel blockers (CCBs), including isradipexcess of new cancers in patients taking short-acting ine, are widely used for the management of hyperCCBs when compared to beta-blockers and angiotentension. 1, 2 Isradipine is a dihydropyridine CCB that sin-converting enzyme (ACE) inhibitors. has been approved by the US Food and Drug Admin-A prospective study (ALLHAT), funded by istration for the treatment of hypertension, alone or NHLBI, is underway to examine the relative effecin combination with other agents, and has been tiveness and safety of various drug regimens, includapproved for the treatment of mild and moderate ing a CCB, in mild and moderate hypertension, but hypertension in JNC guidelines. 3 the results of this study will not be available for sevIn 1995, the results of three studies which queseral years. 12 Similarly, the INSIGHT study, initiated tioned the safety of CCBs were presented at several last year, is enrolling several thousand hypertensive professional meetings and subsequently pubpatients in nine countries to determine the outlished. [4] [5] [6] The study by Psaty et al 4 was a case-concomes with CCBs compared to a diuretic. 13 The final trol study suggesting that the use of CCBs in patients results will not be available for several years. Sevwith hypertension was associated with an increased eral other large scale long term trials have been risk of myocardial infarction. Higher doses were initiated or recently announced, including the STOP associated with increased risk. The study by Furberg Hypertension-2 study of isradipine and felodipine.
14 et al 5 was an update of earlier meta-analyses, 7-10 and Pending the results of these long term outcomes reported on the dose-response relationship between trials, we have performed a systematic review of all immediate release nifedipine and mortality and available randomised controlled trials, both pubfound that nifedipine was associated with signifilished and unpublished, to assess the risk of serious cantly increased risk of mortality in patients with events associated with the use of any formulation of acute coronary syndromes. In 1996, the results of an isradipine as monotherapy in hypertension. trials described previously. 15 A study protocol was more than one investigator was deemed necessary to reduce selection bias as much as possible. prospectively designed to define the study objectives, eligibility criteria for inclusion of trials, key Selected published studies were then blinded as to source, authors, and treatment groups using predata elements to be extracted, and analytical methods to be employed. Studies were selected and viously described methods. [15] [16] [17] Unpublished studies were not blinded. All studies then underwent data were extracted by two investigators working independently. Differences in opinion on study data extraction by at least two reviewers (MD or PhD) using data extraction forms developed at the eligibility and data extraction were resolved in consensus conferences. Data extraction forms were time of the project protocol. Blinded studies were also assessed for quality, using previously described designed and tested prior to implementation. The study was sponsored by Sandoz and one objective of scoring systems, 18 by the same reviewers. Again, all differences were resolved in consensus conference. the study was to compare the sponsor's unpublished results with published studies of isradipine. ComAdministrative and treatment data were extracted independently from unblinded papers. It should be plete study reports received from the sponsor were used for data extraction. The risk of bias due to the noted that the Sandoz-based investigator contributed to project conception, protocol design, and inclusion of unpublished data was addressed in two separate statistical analyses discussed below.
results interpretation, but only MetaWorks investigators selected studies, extracted data and perforTo be included in the meta-analysis, a study had to: (1) be a randomised controlled trial (RCT) enrolmed the analysis. Data were entered from data extraction forms into ling patients with primary hypertension; (2) be either published in a peer reviewed journal or an MetaHub™ for subsequent downloading through ASCII files for analysis using SAS, version 6.11. unpublished randomised controlled trial sponsored by Sandoz or in collaboration with Sandoz; (3) enrol
Prior to downloading for analysis, the computerised data were checked against data extraction forms, a minimum of 10 patients per treatment arm; (4) compare any oral isradipine formulation used as with correction of errors as necessary. monotherapy to a non-CCB active drug or to a placebo control; (5) monitor adverse clinical events and Statistical analysis withdrawals and report them by treatment group;
The analysis plan was directed at answering the foland (6) be of at least 1 week duration. Eligible studlowing questions: ies could be either parallel or crossover study
• Are the major adverse event rates higher during designs. Studies were excluded if the only control treatment of primary hypertension with isradipine arm was a dihydropyridine CCB, or if isradipine was standard therapy or with isradipine sustained given in combination with other active agents.
release therapy then they are during treatment Studies were identified by a MEDLARS search with control regimens composed of other active exploding the MeSH terms 'hypertension' and linkdrugs or placebo? ing it with 'isradipine'. 'Isradipine' was searched as
• Are the rates of withdrawals due to major adverse a textword and as a MeSH heading. All years from events higher during treatment of primary hyper-1986 (the first year of publications for isradipine) tension with isradipine or with isradipine susthrough March 1996 (with the cutoff date of tained release therapy than they are during treat-31 March, 1996) were searched and the following ment with control regimens composed of other languages were included: English, German, French, active drugs or placebo? Spanish, and Italian. CD-ROM Current Contents was
• What is the association of isradipine formulations searched independently. Computer-based searches with the occurrence of major adverse events? were supplemented by manual searches of biblio-
• Are the major adverse event rates from the spongraphies of retrieved papers to detect other potensor's unpublished randomised controlled trials tially acceptable studies. In addition to this, Sandoz similar to published randomised controlled trials? provided data and reports of unpublished randomised controlled trials of isradipine in hypertension All deaths, non-fatal myocardial infarctions, nonfatal strokes, new or increased angina, revasculariswhich MetaWorks also assessed for eligibility using the same criteria as for published studies. Dupliation procedures, cancer, gastrointestinal bleeding, that occurred during the study were classified as cation of published and unpublished studies were avoided by scrupulous comparing of both sets of major adverse events. Total major adverse events were calculated as the sum of the events in the studies for the number of patients included, treatment regimens used, and duration of trial. In cases above groups for each study. Missing values were disregarded and assumed to be zero in this calcuwhere studies were published subsequent to the reports, we made certain that only the published lation.
Withdrawals from the studies were also assessed study was included in our analysis.
Two levels of study screening were employed. and classified by whether they were attributed by the investigator to an adverse effect of the drug regiInitially, all retrieved abstracts and studies were screened by research analysts to exclude animal men or to other causes such as protocol violations, lost to follow-up, or inadequate efficacy. Withstudies, non-qualifying languages, non-randomised controlled trials, and studies that were not clinical drawals for adverse drug effects included those for drug-related symptoms, such as oedema and headtrials of hypertension. Final eligibility of the balance of studies was then determined by the consensus of ache, as well as the more serious clinical events noted above. two independent investigators. Study selection by To be eligible for inclusion in the analysis, rence or the determination of outcomes. The main concern is with carryover effects between phases adverse clinical events and withdrawals must have been assigned by the investigator to a specific study of crossover studies; • the quality score since higher quality studies may arm. Studies were excluded if attribution of withdrawals or adverse event data by study arm was not be associated with more complete reporting of adverse events and reasons for withdrawals; possible. Note that the occurrence of stroke and death have been tabulated both as withdrawals and
• date of study (1989 or earlier vs 1990 or later) which coincides with the introduction of Good as major adverse outcomes in this study.
The occurrence of adverse clinical events was first Clinical Practices (GCPs) in Europe; • publication status; published vs unpublished tabulated by drug regimen and by whether isradipine was prescribed as standard or sustained-release studies may be a surrogate for quality in that most of the unpublished studies are more complete therapy. Control study arms were derived from the same studies as the isradipine arms. Duration of the with respect to adverse event and withdrawal reporting. Any bias in results of unpublished studstudy and length of treatment were included as covariates in a logistic regression model, discussed ies from the sponsor could also be examined and, finally, this may give an estimate of any bias below.
Meta-analyses were performed using two inherent in a meta-analysis of published data (the 'file drawer' problem). 21 methods: odds ratios of dichotomous data were calculated and analysed using both fixed effects models 19 and random effects models 20 using SAS
Results
Version 6.11. Random effects models are more conservative than fixed effects, incorporating inforStudy characteristics mation on study heterogeneity into the model, and therefore considered to be the most appropriate stat-A total of 283 publications were identified as potentially eligible from an overall total of 894 citations istical method for presentation of the results which follow. Odds ratios were used as the outcome of for isradipine. The rejected articles consisted of animal studies, pharmacokinetic studies, other clinical interest if no important differences were observed when outcomes were calculated in other ways, ie, settings besides primary hypertension, or not meeting the predefined protocol criteria. Of the 283 that risk ratios and risk differences. Separate analyses of published and unpublished studies, and for crosswere screened subsequently, 64 appeared to be eligible RCTs and following a final screen by the prinover and parallel studies, were examined for differences. cipal investigator, 32 published studies were completely eligible for inclusion. These studies are The power of detecting a difference between isradipine and control arms was also calculated to ensure listed in the Appendix. Fifty-eight unpublished studies were obtained from the sponsor, and, of that there were sufficient patients to detect a 20% difference in event rates between treatments, should these, 33 were eligible for inclusion in the analysis.
Reasons for rejecting studies included: no reporting one exist. Assuming a two-sided test, with 4500 patients in each treatment arm, there is 80% power of adverse events (published studies only, all unpublished reports included this information), no of detecting between a 20% difference between groups assuming an event rate in the control group withdrawal data (in published studies only, all unpublished reports included this information), of 5%, and 70% power of detecting a 20% difference between groups assuming an event rate in the concombination therapy, fewer than 10 subjects included in the analysis, and comparisons to other trol group of 2.5%. The actual power of detecting the significant difference between isradipine sustained dihydropyridine CCBs. Unpublished study reports from the sponsor were not used if the results were release and control was 98%.
Stepwise logistic regression examined the indealso available in a published study. Table 1 summarises the characteristics of the studpendent effects of study-level covariates on the occurrence of major adverse events and total and ies. A total of 65 studies were analysed, which included 166 study arms, 9903 subjects and 10 675 drug-related withdrawals. Covariates and brief reasons for their inclusion are: treatment exposures. Eighty-three per cent of the studies were of parallel design, and 17% of the studies were of crossover design. Only crossover studies • drug regimen (isradipine vs control) as the primary independent variable of interest; which summarised the clinical events and withdrawals for each study phase were included. A • use of a drug run-in prior to randomisation as a proxy for case severity. Reluctance to take subjects washout period between treatments was included in 63% of the crossover studies. All studies had a plaoff all active medications is assumed to indicate a greater severity of hypertension; cebo or active drug run-in period prior to randomisation. There was a placebo run-in for 94% of studies • duration of treatment because a longer duration of treatment would be expected to be associated with and an active drug run-in for 6% of studies. Forty-three per cent of the parallel studies were an increased risk of adverse outcomes;
• duration of hypertension as a proxy for case sever-у 8 weeks in duration (mean = 10.1 ± 17.2; median = 7 weeks, range = 1 to 144 weeks), and only ity. Longer duration of hypertension may indicate a greater severity of disease; 9% of the crossover studies were у 8 weeks in duration (mean = 5.0 ± 1.6; median = 4 weeks, range = • parallel or crossover study design is used to examine whether study design influences the occur-4 to 9 weeks). The median sample size per treatment trol arms, and 237 in placebo control arms. Because of the variety of reporting of withdrawals (ie, studies may include only total withdrawals and not include subgroups of withdrawals due to administrative arm was 59 for parallel studies (mean = 54.7 ± 18.1; range: 12 to 442 subjects) and 24 for crossover studreasons) no attempt was made to analyse solely administrative (ie, protocol violators) vs non-adminies (mean = 39.4 ± 40.0; range: 12 to 132 subjects). Fifty-four per cent of the subjects were males, the istrative (ie, side effects) withdrawals. Therefore, this group of patients represent an intent-to-treat mean age of all patients in the studies was 56.5 years. All studies were published between 1986 and group as all patients who did not complete the study for any reason were included in the withdrawals 1996 with 65% published since 1990. The mean quality score on the Jadad scale (which has a total analysis. possible range from 0-5) was 3.1 with a range from 2-4. These mean scores are in the low average range Meta-analyses compared to other RCTs. Because of the availability of far greater detail in the unpublished data supplied Results are presented for isradipine vs active controls and vs placebo in separate analyses for total by the sponsor, these studies were rated as of equal or higher quality than published randomised conwithdrawals, major adverse events, and new onset of angina. For isradipine sustained release, there trolled trials. All studies were reported English language.
were sufficient data for comparisons of total withdrawals to placebo controls only. Results for total Total isradipine exposures were 5965 (4492 isradipine and 1473 isradipine sustained release). The withdrawals are given in Figure 1 . Major adverse event data, which included all deaths, are presented comparators totalled 4710 and were composed primarily of 1942 placebo, followed by diuretic, betain Figure 2 , and results for angina in Figure 3 . The overall odds ratios (ORs) for total withblocker, and ACE inhibitors. Data were categorised as active control or placebo control for analyses in drawals was 0.87 (95% CI 0.71-1.07) for isradipine vs active controls and 0.87 (95% CI 0.65-1.16) for this study. Combined overall person-years of exposure and follow-up was 27.3 [31.4 isradipine; isradipine vs placebo. The results for isradipine sustained release vs placebo are similar to isradipine 6.2 isradipine sustained release; 58.4 for active comparators; and 8.6 for placebo].
(OR 0.52, 95% CI 0.31-0.86). For major adverse events, the results showed that Isradipine formulations were used in 58% of the total study arms, and of all isradipine study arms, when isradipine was compared to other active controls or placebo, the risk was similar (OR 0.99; 95% 75% were isradipine and 25% were isradipine sustained release exposures. The starting dose of isradi-CI 0.67-1.46) vs active controls, and (OR 0.52; 95% CI 0.21-1.29) vs placebo. Similar results were pine was 2.5 mg or greater in 71% of subjects, and 5 mg per day or greater in 88% of subjects on isradiobtained for angina only. The OR for isradipine Figure 3 Meta-analysis of isradipine vs controls for angina. Figure 1 Meta-analysis of isradipine vs controls for total withdrawals.
Sensitivity analyses
For this meta-analysis, we were concerned that bias could be introduced by including unpublished data and by including crossover studies. To test the rigor of the results noted above, several additional metaanalyses were calculated. First, meta-analyses were examined which systematically deleted individual studies using a jackknife technique. 19 No individual study inclusion or deletion significantly affected the overall meta-analysis. Next, meta-analyses were run using different groups of included papers, since paper selection is perceived to be a critical reason for observed differences in any meta-analysis. These groups included using either only published or only unpublished studies and using only parallel or crossover studies in the meta-analyses. All gave similar results for withdrawals; adverse events, and angina and the resulting odds ratios were not statistically different from the overall meta-analysis. These results are reported in Table 2 .
Stepwise logistic regression was computed using the log OR of the primary endpoints of total withdrawals, major adverse events, and angina comparing simultaneously the effect of all covariates considered possibly to be related to outcomes. These covariates included publication status, trial design, quality score, length of study, number of random- race, and prior myocardial infarction. With one exception, none of the covariates identified above were significantly related to the log OR in any of the compared to active control was 0.95 (95% CI: 0.60-1.51), and 0.58 (95% CI 0.22-1.51) compared to plafixed effects models. Length of exposure was the only significant covariate in all models examining cebo. The results for isradipine sustained release show no differences when compared to placebo for total withdrawals and the overall incidence of serious adverse clinical events. As expected, the overall either major adverse events in general (OR 0.80; 95% CI 0.26-2.46), or angina (OR 0.77; 95% CI 0.23-occurrence of the events of interest was higher for studies of longer duration. 2.61) (Figures 2 and 3) . reporting of serious adverse events or withdrawals.
Discussion
Lastly, the creation of a relational database of these These results suggest that the risk of serious adverse studies will also now allow relatively straightforevents, including deaths and cardiovascular events, ward updates, as the literature warrants. does not differ in hypertensive patients treated with
We are also cognizant of several limitations to this isradipine or with other active agents or placebo.
approach. First of all, any assessment of relative risk These results apply primarily to the standard release can be misleading when the absolute number of isradipine formulation since these constitute the events is small, as is the case here. The small nummajority of the isradipine treatment exposures. The ber of events is in fact somewhat reassuring, risk of withdrawals was also not significantly differalthough we also recognise that our assumption of ent for isradipine patients compared with those zero events when none were reported may not be receiving active drugs or placebo, and was in fact correct in all cases. Given the serious nature of the significantly lower with the sustained release formuevents of interest, however, we believe that most, if lation than with standard formulations of isradipine. not all, would have been reported had they Most side effect related withdrawals were due to occurred. Also, the absence of any obvious systemsymptoms arising from reflex sympathetic stimuatic difference in reporting of these events between lation, eg, tachycardia, or from vasodilatation, eg, the published studies and the highly detailed oedema and headaches.
unpublished studies supports our assumption. A primary strength of this systematic review and Another concern in interpreting these results meta-analysis is the inclusion of all available pubcentres on the relatively short duration, on average, lished and unpublished randomised controlled of the studies. While long term studies of very large trials. It is very unlikely that any important trials sample size would be necessary (and are underway) were missed. Our adherence to rigorous methods for to conclusively demonstrate efficacy in preventing screening and selecting studies, blinding published adverse cardiovascular outcomes, we believe that papers prior to data extraction, and using dual these shorter term, smaller studies are in fact useful extraction by two investigators serves the purpose in assessing safety. Cardiovascular events in hyperof reducing bias and error as much as possible. The tensive patients receiving antihypertensive treatthorough exploration of the robustness of the analyments could represent a treatment-related adverse sis using multivariate techniques, including muleffect or a lack of efficacy. Smaller studies of shorter tiple logistic regression and sensitivity analyses, duration are more likely to demonstrate the former also increases confidence in the results. The sensithan the latter. tivity analyses are of particular interest since they suggest that publication status did not impact the Also, we could not adjust per-person rates for the 
